Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2004

01-03-2004 | Review

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

Authors: Pedro Romero, Jean-Charles Cerottini, Daniel E. Speiser

Published in: Cancer Immunology, Immunotherapy | Issue 3/2004

Login to get access

Abstract

Numerous phase I and II clinical trials testing the safety and immunogenicity of various peptide vaccine formulations based on CTL-defined tumor antigens in cancer patients have been reported during the last 7 years. While specific T-cell responses can be detected in a variable fraction of immunized patients, an even smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring antitumor T- and B-cell responses and at sustaining a large number of tumor antigen specific and fully functional effector T cells at tumor sites. Recent progress in our ability to quantitatively and qualitatively monitor tumor antigen specific CD8 T-cell responses will greatly help in making rapid progress in this field.
Literature
1.
Koff RS. (2002) Immunogenicity of hepatitis B vaccines: Implications for immune memory. Vaccine 20:3695CrossRefPubMed
2.
Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU, Pops Investigators (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645
3.
Das K, Gupta RK, Kumar V, Kar P (2003) Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders. World J Gastroenterol 9:1132PubMed
4.
Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94PubMed
5.
Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T, Hengartner H, Zinkernagel R (1998) Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 187:1383CrossRefPubMed
6.
Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, Lienard D, Lejeune F, Cerottini JC, Romero P (2001) Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 166:7634PubMed
7.
Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ, Blankenstein T (2001) Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 7:1159PubMed
8.
Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677PubMed
9.
Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Lienard D, Keilholz U (2002) Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 62:1743PubMed
10.
Rufer N, Zippelius A, Batard P, Pittet M, Kurth I, Corthesy P, Cerottini JC, Leyvraz S, Roosnek E, Nabholz M, Romero P (2003) Ex-vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 102:1779
11.
Liu L, Chahroudi A, Silvestri G, Wernett ME, Kaiser WJ, Safrit JT, Komoriya A, Altman JD, Packard BZ, Feinberg MB (2002) Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 8:185CrossRefPubMed
12.
Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98:10290PubMed
13.
Coulie PG, Lurquin C, Colau D, Connerotte T, Hanagiri T, van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, van Baren N, Boon T (2002) Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 188:33CrossRefPubMed
14.
Smith JWI, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu H-M, Romero P, Alvord WG, Urba WJ (2003) Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 21:1562CrossRefPubMed
15.
Valmori D, Pittet M, Vonarbourg C, Rimoldi D, Lienard D, Speiser D, Dunbar PR, Cerundolo V, Cerottini JC, Romero P (1999) Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide. Cancer Res 59:4050PubMed
16.
Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Lienard D, Guillaume P, Romero P, Cerottini JC, Rimoldi D (2001) Frequent cytolytic T-cell responses to peptide MAGE-A10(254–262) in melanoma. Cancer Res 61:509PubMed
17.
Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60:4499PubMed
18.
Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Levy F (2002) Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 168:1717PubMed
19.
Zippelius A, Pittet MJ, Batard P, Rufer N, de Smedt M, Guillaume P, Ellefsen K, Valmori D, Lienard D, Plum J, MacDonald HR, Speiser DE, Cerottini JC, Romero P (2002) Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 195:485CrossRefPubMed
20.
Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190:705CrossRefPubMed
21.
Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641CrossRefPubMed
22.
Pittet M, Zippelius A, Valmori D, Speiser D, Cerottini JC, Romero P (2002) Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol 23:325CrossRefPubMed
23.
Speiser D, Lienard D, Pittet M, Batard P, Rimoldi D, Guillaume P, Cerottini JC, Romero P (2002) In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 32:731CrossRefPubMed
24.
Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3:37PubMed
25.
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321PubMed
26.
Pittet MJ, Speiser DE, Lienard D, Valmori D, Guillaume P, Dutoit V, Rimoldi D, Lejeune F, Cerottini JC, Romero P (2001) Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 7:796sPubMed
27.
Valmori D, Dutoit V, Schnuriger V et al (2002) Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 168:4231PubMed
28.
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643PubMed
29.
Moingeon P, Leclerc C (2002) Challenges and issues in new vaccine development. Trends Immunol 23:173CrossRefPubMed
30.
Dutoit V, Taub RN, Papadopoulos KP et al (2002) Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110:1813CrossRefPubMed
31.
Haanen JB, van Oijen MG, Tirion F, Oomen LC, Kruisbeek AM, Vyth-Dreese FA, Schumacher TN (2000) In situ detection of virus- and tumor-specific T-cell immunity. Nat Med 6:1056CrossRefPubMed
32.
Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, Haase AT (2000) Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues. J Immunol 165:613PubMed
33.
Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964PubMed
34.
Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN, Haanen JB, Mutis T, Goulmy E (2002) In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 8:410CrossRefPubMed
35.
Wang E, Miller LD, Ohnmacht GA et al (2002) Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62:3581
36.
Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181PubMed
37.
Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380PubMed
38.
Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen Y, Knuth A, Old LJ (2003) Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proc Natl Acad Sci USA 100:8862CrossRefPubMed
39.
Wang RF (2002) Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 188:65CrossRefPubMed
40.
Cameron TO, Norris PJ, Patel A, Moulon C, Rosenberg ES, Mellins ED, Wedderburn LR, Stern LJ (2002) Labeling antigen-specific CD4+ T cells with class II MHC oligomers. J Immunol Methods 268:51PubMed
41.
Reijonen H, Kwok WW (2003) Use of HLA class II tetramers in tracking antigen-specific T cells and maping of T-cell epitopes. Methods 29:282CrossRefPubMed
42.
Marchand M, van Baren N, Weynants P et al (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA- A1. Int J Cancer 80:219PubMed
43.
Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54PubMed
44.
Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM (1998) Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 76:817CrossRefPubMed
45.
Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J (2001) Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19:3836PubMed
46.
van Driel WJ, Ressing ME, Kenter GG et al (1999) Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35:946CrossRefPubMed
47.
Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95:1781PubMed
48.
Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, Thiel E, Schadendorf D (2000) Phase 2 trial of vaccination with tyrosinase peptides and granulocyte- macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23:275CrossRefPubMed
49.
Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406PubMed
50.
Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477PubMed
51.
Phan GQ, Touloukian CE, Yang JC et al (2003) Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26:349CrossRefPubMed
52.
Bettinotti MP, Panelli M, Ruppe E, Mocellin S, Phan GQ, White DE, Marincola FM (2003) Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170–178. Int J Cancer 105:210CrossRefPubMed
53.
Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Conway G, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS (2003) A phase I trial of SD-9427 (Progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 9:1301PubMed
54.
Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K, Tamura M, Yamada A, Morinaga A, Nishikori M, Katagiri K, Itoh K, Yamana H, Hashimoto T (2003) Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother 26:357CrossRefPubMed
55.
Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21:2342CrossRefPubMed
56.
Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372CrossRefPubMed
57.
Gnjatic S, Jager E, Chen W, Altorki NK, Matsuo M, Lee SY, Chen Q, Nagata Y, Atanac Kovic D, Chen YT, Ritter G, Cebon J, Knuth A, Old LS (2002) CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA 99:11813
Metadata
Title
Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination
Authors
Pedro Romero
Jean-Charles Cerottini
Daniel E. Speiser
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0473-9

Other articles of this Issue 3/2004

Cancer Immunology, Immunotherapy 3/2004 Go to the issue

Review

Immunological inhibition of carcinogenesis

Review

Tumour escape: antitumour effectors too much of a good thing?

Review

A primer on cancer immunology and immunotherapy

Review

The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy

Review

Exosome-based immunotherapy

Review

Apoptosis pathways in cancer and cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits